Levetiracetam – Risk of Drug Reaction With Eosinophilia and Systemic Symptoms (Dress)

Home > Levetiracetam – Risk of Drug Reaction With Eosinophilia and Systemic Symptoms (Dress)

27 Mar Levetiracetam – Risk of Drug Reaction With Eosinophilia and Systemic Symptoms (Dress)

Posted at 08:55h in by

The following pharmaceutical companies, GlaxoSmithKline (GSK) South Africa, Ranbaxy Pharmaceuticals (Pty) Ltd South Africa, Pharma Dynamics (Pty) Ltd, Unicorn Pharmaceuticals (Pty) Ltd, Cipla Medpro (Pty) Ltd, Hetero Drugs South Africa (Pty) Ltd, Dr Reddy’s Laboratories (Pty) Ltd, in collaboration with the South African Health Products Regulatory Authority (SAHPRA), would like to inform you about the potential risk of drug reaction with eosinophilia and systemic symptoms (DRESS) associated with the use of levetiracetam containing medicines.

Download latest version
Document Number: DHCPL
Version: 1
Date Updated: 27/03/2026
File Type: www
Category: Communication To Health Care Professionals
Unit: Pharmacovigilance